Hanwha Offers Up to $1.2 Billion for Austal US Business 
ADNOC Gas Targets Up to $4B Profit in 2026 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Airbus Joins Air India A320 Altitude Drop Probe 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Dublin, Feb. 16, 2018 -- The "Biosimilar Insulin Market Access" report has been added to ResearchAndMarkets.com's offering.
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants Toujeo and Tresiba.
More aggressive payers are excluding branded insulin products in favor of the less expensive biosimilar, forcing switches in existing patient populations. As such, manufacturers of branded insulin products will need to offer deeper discounts to remain on payers' formularies and contracts.
Key Topics Covered:
EXECUTIVE SUMMARY
US
- Insights and strategic recommendations
- US payers are adopting a wait-and-see approach for biosimilar Basaglar
- Bibliography
FIVE MAJOR EU MARKETS
- Insights and strategic recommendations
- Uptake of biosimilar insulin varies across EU markets as the EMA does not determine interchangeability
- Physicians and payers have varying views on the interchangeability of biosimilar insulins, but see large opportunities to
- reduce costs
- Payers use biosimilars to pressure originators on pricing
- Pharmacies continue to procure both biosimilars and originators; dynamic pricing environment observed
- Patient switching requires significant discounts of at least 30%
- Given attractive discounts, payers will use a variety of market access tools to drive Basaglar's uptake
- Bibliography
METHODOLOGY
For more information about this report visit https://www.researchandmarkets.com/research/64x5p8/european_and_us?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Biosimilars and Biosuperiors
